Ondine Biomedical Inc.



888 – 1100 Melville Street
V6E 4A6


Fax: 604-669-0533

Member Sector: Biopharmaceuticals

Ondine Biomedical Inc. is developing non-antibiotic therapies for the treatment of a wide variety of complex bacterial, fungal and viral infections. The Company is focused on developing and commercializing innovative products using its patented light-activated platform technology, Photodynamic disinfection (PDD). PDD eradicates pathogens by using a non-thermal light source with a specific wave length and a photosensitizing solution that selectively stains the targeted pathogens. The PDD treatment does not harm human tissue and provides an immediate broad-spectrum antimicrobial efficacy without the development of bacterial resistance to the therapy. Ondine’s first product, Periowaveâ„¢, was introduced into the dental market in 2006 for the treatment of periodontal disease. Ondine’s second product, MRSAidâ„¢, is for decolonization of pathogens from the nares of pre-operative hospital patients. MRSAidâ„¢ was introduced in later part of 2012 at the conclusion of its successful deployment in a quality improvement project conducted at Vancouver General Hospital. Ondine continues to develop a number of other applications of PDD, including Exelumeâ„¢, which eradicates bacterial biofilms on the inner surface of endotracheal tubes thereby reducing the risk to patients on long-term intubation of contracting ventilator-associated pneumonia. Ondine is headquartered in Vancouver, British Columbia, Canada, and has a research and development laboratory in Bothell, Washington, USA.